Results of the present study demonstrated that ICS II is a promising PDE5 inhibitor that modulates intracellular oxidative activity and antioxidant response in rat neuronal PC12 cells, hence having therapeutic potential in redox‐mediated neurological diseases. The gene discussed is PDE5A; the disease is nervous system disorder.